Medical Marketing and Media | Analyst: Don't underestimate AbbVie Medical Marketing and Media Rubin pointed out that the MS drug daclizumab, which is being developed with Biogen Idec, has safety and tolerability issues that undercut its efficacy profile. Rubin said heat surrounding new oral agents “with less safety concerns,” limit the ... |
